To the Editor
The manuscript by Flodmark et al. [1] recently published in the open-access journal Biologics in Therapy describes a single-center experience in Sweden of a switch from an originator biologic to a biosimilar human growth hormone (rhGH) using a dialogue teamwork approach [1] . Unfortunately, the authors fail to mention several limitations to their study which call into question their conclusions.
To evaluate the effect on growth of switching from originator to biosimilar rhGH, Flodmark et al. [2] Later in the paper, the authors comment that the switch of device types is not necessary without a consequence in that ''switching to a different rhGH product also involves the use of a new injection device. Consequently, patients must learn, and get used to, a different injection technique''. Previous studies of ease of use of injection devices [4] suggest that not all devices are similar in ease of use. In addition, as pointed out by Grimberg et al. [5] , both clinic costs and non-compliance risks associated with switching are not inconsequential. Flodmark et al.
included neither in their assessment of outcome. This oversight is complicated by a failure of the authors to address the cost of switching when calculating the economic benefit of the switch incurred due to differences in product cost. One would expect that all costs and benefits be considered in a rigorous economic analysis. Finally, the authors report that patients were given a choice of switching to biosimilar rhGH or paying for the difference in cost between their own product and the biosimilar. Since the originator biologic was reimbursed by the government it is not clear on what grounds the clinic could have charged the patients and indeed four patients were allowed to continue without contributing to the cost of therapy.
These limitations, together with a lack of a cautionary note on the danger of overinterpretation of the result from this noninterventional study, raise questions regarding the validity of the study and its conclusions.
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